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Though the MMA offers a huge number and range of potential subjects,
the discussion was focused around four primary areas: eligibility, enroll-
ment, and outreach; the transition for dual eligibles; financing challenges;
and administrative and systems issues. Each of these areas is discussed
briefly below. The final section of this report contains a list of summary
observations from the meeting.
This report is not meant to provide extensive details or to define issues as
legislative, regulatory, state, or federal, and the Forum does not intend to
use this publication to propose specific recommendations or solutions to
problems. Rather, the objective is to provide a general understanding of
the problems expressed by state experts so that more attention will be
directed to these problems by appropriate officials at both the state and
federal level. (It should be noted that the Notice of Proposed Rule Mak-
ing (NPRM), or draft regulation, governing the implementation of the
MMA was released by CMS just a few days after the meeting. A few of the
issues discussed at the Forum session were somewhat clarified in that
NPRM; however, most issues still require additional consideration and
clarification.) As always, NHPF hopes to assist beneficiaries, advocates,
researchers, and other MMA stakeholders by providing a sharper under-
standing of the difficulties faced by states as the new Medicare drug ben-
efit becomes available in January 2006.
INTRODUCTION
The National Health Policy Forum convened a meeting on July 22, 2004
to discuss state-based challenges associated with implementing the new
Medicare drug benefit. The meeting brought together an extremely in-
sightful and experienced group of current and former state officials and
other experts to discuss key issues. In keeping with its tradition of pro-
moting a frank, off-the-record exchange on health policy issues, NHPF
does not normally prepare written summaries or reports of meetings.
However, because this meeting provided vivid illustrations of the impor-
tance of state-federal collaboration for the successful implementation of
the new drug benefit under Part D of the Medicare Prescription Drug,
Improvement, and Modernization Act (MMA), participants agreed that
the information should be shared more widely. Thus, this report is in-
tended to provide a candid montage of the July 22 meeting and supply
additional information and insights into state issues surrounding MMA
implementation. An agenda for the meeting, as well as a list of partici-
pants, is attached to this report (Appendix C).
The meeting was structured as a facilitated but informal dialog designed
to identify and clarify issues and to promote problem solving. The intent
was to encourage the maximum participation of state experts on both
Medicaid and pharmacy assistance programs while also providing an op-
portunity for a small audience of about 60 participants to ask questions
and offer comments. This was a difficult undertaking in the time allotted,
but the meeting provided some significant insights that the Forum hopes
will be taken up in future discussions and activities.
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BACKGROUND
When the new prescription drug benefit is implemented in 2006, it will
make drug coverage available for the first time to all Medicare beneficia-
ries. Some of these beneficiaries are now covered by retiree health benefits,
supplemental Medigap plans, and Medicaid or other state-funded pro-
grams, but at least 13 million seniors—nearly 40 percent of Medicare ben-
eficiaries—have a major gap in health coverage and are required to pay
out-of-pocket for the entire cost of their prescription drugs.1 States have
responded to this gap in coverage primarily through Medicaid programs
and through the creation of state pharmacy assistance programs (SPAPs).
State Medicaid programs provide comprehensive prescription drug cover-
age for 6 million low-income elderly and disabled Medicare beneficiaries.
Known as “dual eligibles,” these individuals rely heavily on the Medicaid
program to provide the services that Medicare does not cover. (See Appen-
dix A for more information on dual eligibles.) Although drugs are an
optional Medicaid service, all states have provided a prescription drug ben-
efit to eligible Medicaid beneficiaries for many years. Therefore, Medicaid
has, until now, effectively filled this gap in Medicare prescription drug cov-
erage for dual eligibles. In addition, many states have separately funded
and established SPAPs to cover a portion of drug expenses for other low-
income people who do not receive Medicaid. In 29 states, SPAPs provide
subsidies and discounts to elderly and, in many cases, disabled individu-
als with a wider range of incomes.2 The new Medicare drug benefit pre-
sents a myriad of potential new challenges and many major changes for
those low-income people who already have drug coverage through Medic-
aid or an SPAP, as well as the states that have been serving them.
ELIGIBILITY, ENROLLMENT, AND OUTREACH
Beginning in January 2006, the MMA requires that all individuals who are
eligible for both Medicare and Medicaid begin receiving their prescription
drugs through the Medicare Part D program. This change will result in a
significant shift in benefits for elderly and disabled dual eligible beneficia-
ries because they will receive their drugs through a prescription drug plan
(PDP) rather than through the state. States have primary responsibility for
determining eligibility and enrolling individuals in their Medicaid pro-
grams, and the MMA requires that states continue that responsibility in
implementing a new “low-income subsidy” program that will be available
under Part D. The statute and proposed regulation also require the Social
Security Administration (SSA) to be available to make eligibility determi-
nations for the low-income subsidies, but they do not specify how or what
the interaction with states should be. (See Appendix B for specific infor-
mation about the low-income subsidy programs.)
The creation of the low-income subsidy program, designed to assist
dual eligibles and other low-income individuals with the cost-sharing
requirements associated with the Medicare drug benefit, will have a
Medicaid has, until
now, effectively filled
this gap in prescription
drug coverage for dual
eligibles.
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major impact on states. Individuals can apply for the subsidy either
through the state Medicaid agency or through SSA.
While the income eligibility requirements for the subsidies (up to 150 per-
cent of the federal poverty level, which was $13,965 for an individual in
2004) are very similar to those currently used in Medicaid programs, the
MMA includes a new asset test requirement. Asset tests are designed to
take into account an individual’s savings and other investments when de-
termining eligibility. The new asset tests (ranging from $6,000 to $10,000
for individuals and $9,000 to $20,000 for couples) are more generous than
those used by most states in Medicaid programs, which will add an addi-
tional layer of complexity for states attempting to facilitate enrollment for
these individuals. In addition, SPAPs generally have not used asset tests,
so (a) extra effort will be required in assisting SPAP enrollees in the transi-
tion to Medicare and (b) some SPAP-eligible individuals will not qualify
for a low-income subsidy program because they have too many assets.
Despite these challenges, the first order of business for states will be to iden-
tify low-income people who are eligible for the MMA drug benefit, deter-
mine processes to enroll these eligibles, and develop education, information,
and outreach programs so that beneficiaries will learn of and become in-
formed about the new benefit. Among the most important eligibility, en-
rollment, and outreach issues discussed on July 22 are the following:
■ The responsibility for eligibility determinations under MMA is
assigned to both states and SSA. Not only is there a potential for
confusion, overlap, and duplication of effort between these entities,
the lack of existing state-SSA communications and complementary
information systems present major roadblocks. The fact that nearly
half of the states—including large states like New York, New Jersey,
California, and Ohio—involve or require counties to make eligibility
determinations, enroll eligible people, and provide outreach and
education, further complicates this problem. SPAPs, often found in
large states with long-standing programs, face similar concerns.
■ The asset test required by MMA will be different than those used
currently by most states, and there is no clear crosswalk from the
old to the new asset test for beneficiaries. At a time when the trend
has been for states to simplify their Medicaid eligibility and enroll-
ment procedures and move to self-declaration of income or assets, the
MMA asset test reinstates some old complexities, creating barriers to
enrollment. State representatives voiced particular concerns about
how many “gray areas” there are in applying asset tests, including,
for example, the valuing of many types of life insurance, vehicles such
as snowmobiles, and other items not clearly specified in the statute.
The proposed regulation attempts to clarify this definition, asserting
that only “liquid” assets, such as bank accounts, stocks, and bonds
that can be converted to cash within 20 days (as well as real estate that
is not considered the primary residence) will be counted, but compli-
cations will still abound.
Asset tests are de-
signed to take into ac-
count an individual’s
savings and other in-
vestments when de-
termining eligibility.
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■ The new MMA drug benefit is optional. That is, beneficiaries must
make a positive declaration and choice to enroll in the program, as
well choose a Medicare Advantage (MA) plan or PDP drug provider.
In addition, individuals who do not choose to enroll during the initial
enrollment period will be required to pay a penalty in addition to the
premium when they do enroll. While the concept of “choice” is
important, for many dual eligibles and others now served by state
programs (particularly those who have cognitive or severe medical
problems) these features will likely complicate the outreach, eligibil-
ity, and enrollment process. Although automatic enrollment3 could
facilitate these choices for many individuals, concerns about ensuring
that these individuals are adequately represented remain.
■ Intermittent eligibility in Medicaid programs may further compli-
cate the transition to Part D and disrupt access to prescription drugs.
Unique Medicaid “spend down” or “medically needy”4 programs
operate in 39 states. These programs allow people with high medical
costs, including nursing home residents, to qualify for Medicaid by
spending their income and resources down to a state-defined medical
assistance eligibility level. In many cases, an individual may begin a
month with a pension check or other source of income that makes them
ineligible for Medicaid for the first part of the month, but once that
income is put toward the cost of their care (that is, spent down), they
become eligible for the remainder of the month. Depending on the
spend down period designed by the state, individuals can cycle on and
off of Medicaid eligibility on as often as a monthly basis. This intermit-
tent eligibility will significantly complicate the initial education and
enrollment process and must be factored in to continuing administra-
tive and policy decisions for states, the federal government, and pro-
viders of prescription drug benefits.
■ The need for clarity around the use of auto-enrollment processes
and the ability of state Medicaid and/or SPAP programs to “wrap
around” the Part D benefit was stressed by all state officials. The
NPRM suggests that auto-enrollment will be available for those “full
benefit dual eligibles” who are transitioning to the Medicare drug
benefit, in hopes of making the process seamless for these particularly
vulnerable beneficiaries. However, CMS has also indicated that it does
not have authority to auto-enroll individuals who are currently enrolled
in Medicaid Savings Programs (not considered full benefit dual eli-
gibles). These individuals, also commonly referred to as QMBs, SLMBs,
and QIs receive assistance through Medicaid with Medicare cost sharing
but do not receive full Medicaid benefits (see Appendix A for further
explanation). The use of auto-enrollment, a technique many states have
used successfully in their Medicaid managed care plans, is seen as an
important potential administrative tool by states. However, language in
the proposed regulation has caused some confusion in this area and has
generated significant debate among beneficiary and state advocates.
Depending on the
spend down period
designed by the state,
individuals can cycle
on and off of Medic-
aid eligibility as often
as  monthly.
6NHPF Meeting Report August 31, 2004
■ Some seniors have avoided programs for which they qualify be-
cause of the stigma they perceive to be associated with state Medicaid
eligibility processes. In fact, some SPAP programs were set up with this
very concern in mind. Other beneficiaries, however, have become accus-
tomed to dealing with specific state or county workers and may not
understand that they do not have to change their existing relationships.
Particularly in the early days of outreach and enrollment, the potential
for confusion, duplication, and frustration for beneficiaries, states, and
SSA will be high. These issues could be further complicated for individu-
als who reside for part of the year outside the state that is their primary
residence, particularly if they happen to be at their secondary residence
during the open enrollment period. Clear information for beneficiaries
about where to go for assistance must be reflected in national, state, and
local educational efforts. In addition, streamlining and standardizing
applications and verification procedures will be critical in ensuring that
all Medicare beneficiaries receive the same treatment.
■ Education, information, and outreach efforts and responsibilities
will be spread among a large number of state, federal, private
provider, and advocacy organizations. Because each state will be
different in terms of its organization, structure, laws, and require-
ments, a uniform national effort will be difficult. Coordination will be
a particular challenge.
THE TRANSITION FOR DUAL ELIGIBLES
Beyond eligibility, enrollment, and outreach, there are other specific
concerns related to serving dual eligible people who are currently re-
ceiving drugs through their state’s Medicaid program. Elderly and dis-
abled beneficiaries who are dually eligible for both Medicare and
Medicaid are among the most frail, vulnerable, and ill people in the
country. Known for their high cost and complex health needs, many
live in nursing homes and have cognitive impairments and multiple
medical problems, all conditions that can limit their ability to live inde-
pendently and make informed choices. Finally, there are major
differences between elderly Medicare beneficiaries and Medicare ben-
eficiaries who are eligible because of a disability. These two groups of
people have distinct problems and should not be lumped together in
the design of programs to assist them. Thus, managing the transition
for dual eligibles will be particularly risky when the new Medicare drug
benefit begins and disrupts existing processes for accessing prescrip-
tion drugs. A number of very important issues surfaced at the July 22
session, including:
■ For those residing in nursing homes, questions related to eligibil-
ity and enrollment, along with the “optional” nature of the Part D
benefit and the requirements for choice, must be addressed. In
many nursing facilities, Medicaid prescription drugs are provided by
large, specialized institutional pharmacies and paid for directly by the
The potential for con-
fusion, duplication,
and frustration for
beneficiaries, states,
and SSA will be high.
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Medicaid agency, not by the nursing facility. Medicaid nursing facility
residents are not accustomed to choosing the source of their prescrip-
tion drugs. Who will provide outreach, education and enrollment
services in nursing homes? Should a special enrollment process be
developed for this population? Who has the authority to act on behalf
of these vulnerable beneficiaries? Should special safeguards be em-
ployed in designing systems for this group?
■ The adequacy of the Part D formularies offered to dual eligibles
will be a key concern. The MMA provides flexibility for PDPs and MA
plans to decide which drugs will be covered and which will be limited
or excluded. Therefore, it is possible, or even likely, that many plans’
formularies will be less comprehensive than what Medicaid has pro-
vided. States’ grievance and appeals systems will also be critical to this
population if certain drugs are not available under a formulary.
■ Administrative techniques to distribute drugs to dual eligibles will
change and could negatively impact both providers and beneficia-
ries. Because nursing homes utilize a different distribution channel for
prescription drugs, often involving entities other than traditional PBMs,
the transition to the new benefit will be complicated for residents of
nursing facilities. The new drug distribution channels could also be
restrictive for individuals currently receiving home and community-
based services through Medicaid. For example, in the commercial
insurance world, the delivery of maintenance medications for chronic
illnesses is increasingly moving to a mandatory mail-order arrange-
ment. Though more cost effective by far, this approach could be prob-
lematic for individuals requiring an institutional level of care.
■ For both MA plans and PDPs, the potential for adverse selection if
a large number of dual eligibles enrolls in the plan will be a signifi-
cant concern. Similarly, there is a concern that vendors might devise
strategies to avoid enrolling dual eligibles, for fear of adverse selection.
It is not clear at this point whether CMS payment rates for MA plans
and PDPs will be adequately justified to reflect this risk.
■ Care coordination and transitions for dual eligibles, while always
difficult, will become even more complex. The potential addition of
new care managers could easily lead to significant overlaps and
duplication of effort. For example, a dual eligible might be managed
by his or her MA or PDP plan while living at home, but if that indi-
vidual then had to be hospitalized, all the drugs would be included in
the per diem or DRG (diagnosis-related group) payment at the hospi-
tal. And if that person further had to be moved to a nursing facility,
the drugs and the care could be managed and provided by another
Medicare plan as well as by the Medicaid agency. States expressed
concerns about transitions for people when they are clearly not well
and probably have limited capacity to make sound choices. The
communication and financing challenges are daunting.
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■ Medicare and Medicaid data about this special population has never
been efficiently (if at all) shared among and between CMS and the
states. The transition to the new drug benefit further hinders states’ ability
to track drug usage and expenditures for dual eligibles. In addition, drug
files are often the only source of information Medicaid agencies have about
disease prevalence in a population. The transition also raises questions
about how and whether they will be able to get access to this information
in a timely fashion in order to serve dual eligibles and to try to keep these
beneficiaries in optimum health and with maximum functionality.
■ Medicaid now provides a significant amount of over-the-counter
drug coverage to dual eligibles. Although states may continue to do so
after Medicare takes over prescription benefits, it is not clear that the
incentives will support this decision. In addition, there are questions
about how or whether Medicaid will provide wrap-around coverage for
prescription drugs that may not be available to dual eligibles through
Part D (see sidebar).
Mental Health: A Case Study
Participants on July 22 discussed mental health issues and the unique situation that might exist for
patients with severe and persistent mental illness, as a kind of case study under the general rubric of
dual eligibles. This population, usually eligible for Medicare and Medicaid under the disability
qualification because of a mental health diagnosis, can lead productive lives if their treatment—
including prescription drugs—is appropriate and adequate. However, providing such care involves
a great  number of people and significant expense. A review of Medicaid data in one state indicated,
for example, that 10 percent of all schizophrenics are dual eligibles, representing 25 percent of the
total service and pharmacy costs of duals.* These significant costs heighten concerns about serving
those in this population.
Effective treatment of severe mental illness usually requires access to appropriate psychotropic drugs,
the newer of which, as noted, are often quite costly. Even if older drugs are classified in the same
therapeutic category, most are not clinically interchangeable. The new system of competitive plans
and distinctive closed formularies could adversely affect the availability of these drugs. And
transitioning mentally ill patients from one medication to another, which could be necessary under
the competitive drug plan and formulary system, is a difficult and complex clinical task that could
have significant impacts on the quality and effectiveness of patient care.
For mentally ill people, access to the right treatment can mean clinical stability, ability to function in
the community, and reduced overall cost of health care. Severely mentally ill patients can maintain
normal functioning with appropriate drugs and care. Without it, they may have to be hospitalized.
Concerns noted in “The Transition for Dual Eligibles” section of this report about grievance and ap-
peals systems, as well as adverse selection, are particularly relevant for patients with mental illness
who rely on particular psychotropic drugs.
*Comprehensive Neuroscience, Inc., and the Missouri Office of Medicaid, “Missouri Medicaid Data Analysis of Dual Eligible
Beneficiaries,” unpublished data, July 2004.
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FINANCING CHALLENGES
The MMA has a number of financial implications for states, primarily
related to Medicaid. Perhaps the largest change will affect states both
monetarily and on a broader, philosophical level regarding the state-
federal Medicaid partnership. The “phased-down state contribution,”
more commonly known as “the clawback,” creates for the first time a
flow of funds from states back to the federal government. The clawback
was created in the MMA conference committee discussions to help pro-
vide adequate funding for the new Medicare drug benefit. Beginning in
FY 2006, states will be required to make a monthly payment to the federal
government to, in effect, re-direct the money that the states would have
spent on providing prescription drugs to beneficiaries in Medicaid. The
clawback will consist of a monthly calculation based on the combination
of (a) the state’s per capita spending on prescription drugs in 2003, (b) the
state Medicaid matching rate, (c) the number of dual eligibles residing in
the state, and (d) a “phase-down percentage” of state savings to be re-
turned to the federal government, beginning with 90 percent in 2006 and
phasing down to 75 percent in 2015.5
The clawback was designed with the expectation that states would re-
ceive a fiscal windfall when a large portion of their Medicaid prescrip-
tion drug costs shift to Medicare. However, the calculations associated
with determining the clawback payments are fraught with technical and
political complications.
State concerns around financial issues related to the new drug benefit are
discussed below.
Technical Concerns
■ The definition of 2003 as the base year for the clawback is a
source of concern for states. As the state budget crises continued, by
2003 most states were taking aggressive actions to control costs and
many looked to drug utilization review and other administrative
savings techniques as a means of keeping Medicaid drug spending in
check. The savings that will be generated by these efforts will not be
realized until at least 2004, thus the base numbers for 2003 will most
likely be overstated for many states. In addition, the Medicaid federal
and supplemental drug rebates from 2003 will not be reflected at the
time the clawback calculation is made. In fact, the Congressional
Budget Office’s estimate suggests that the majority of the net relief
will come to states between 2010 and 2015.6
■ Inadequate Medicaid administrative data systems will make the
calculation of the clawback difficult for states. In addition, the re-
quirement for monthly payments to the federal government is a major
departure from the existing quarterly reporting structures.
“The clawback” cre-
ates for the first time
a flow of funds from
states back to the fed-
eral government.
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Policy Concerns
■ The number of dual eligibles has a significant effect on states’
Medicaid costs. The number of dual eligibles in the state could go up
or down with accompanying increases or decreases in overall state
spending. It is expected that state outreach and education efforts will
result in a “woodwork” effect in Medicaid. CMS suggests that 1 million
additional dual eligibles will be enrolled nationwide. Because the
clawback calculation is based on the number of dual eligibles who
enroll in the Part D drug benefit, states may have an increased incentive
to control costs in ways that could be detrimental to beneficiaries.
Depending on the future economy, states could feel compelled to limit
the number of duals by cutting back the number or types of optional
Medicaid eligibility groups, limiting or cutting benefits (such as over-
the-counter drugs), or by limiting state outreach efforts.
■ States will have greatly reduced bargaining power under the drug
rebate program after MMA is implemented. States currently are the
largest purchasers of many drugs in the United States and receive
substantial rebates based on getting the “best price” as a large pur-
chaser, either through the primary Medicaid drug rebate program or
through supplemental programs they have negotiated. Because about
half of current Medicaid drug expenditures are for dual eligibles, the
MMA benefit will result in significantly reduced bargaining power for
states as the purchasing for this group shifts to Medicare.
■ More prosperous states that have historically offered more gener-
ous Medicaid coverage will be disproportionately affected by the
clawback. These states will continue to receive only the minimum 50
percent federal matching rate, but they will pay at higher rates under
the clawback, despite the theoretical shift to federal funding of the
prescription drug benefit.
■ Positive effects of MMA on state finances relate to the states’ role as
employer and provider of retiree health benefits. There is potential for
a substantial offset to states in retiree health costs under the provisions of
Part D. Another potential area for state savings is through the new
specialized plans targeted at serving dual eligibles to integrate and better
manage their drug and health costs under both Medicare and Medicaid.
ADMINISTRATIVE AND SYSTEMS ISSUES
Medicaid is structured as a federal-state partnership; the state’s role is to
provide day-to-day administration of the program within broad federal
rules and guidelines. States develop procedures for determining eligibil-
ity, enrolling beneficiaries, contracting with or credentialing providers,
and processing claims. They create information and reporting systems to
manage their programs. These reporting and management systems are
different in every state and exist within a unique political and adminis-
trative climate. They are governed by different administrative procedures
The MMA benefit will
result in significantly
reduced bargaining
power for states as
the purchasing for
this group shifts to
Medicare.
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requirements, exist in different state government agencies, and have dis-
similar relationships with other state health, welfare, and social service pro-
grams. The old saying, which applies to administration as well as policy
aspects of the program, is “If you’ve seen one Medicaid program, you’ve
seen one Medicaid program.” Each state has distinct information systems
and idiosyncratic state laws and regulations to govern Medicaid, pharmacy
assistance, and related programs, as well as different relationships with
CMS, SSA, and other federal agencies. Overlaying a new federal drug
benefit on 51 jurisdictions and the territories will not be easily accom-
plished in an administrative sense. Among the concerns expressed in this
regard by July 22 participants are the following:
■ “It is already too late for state system changes.” Information tech-
nology systems will have to undergo major reconfigurations to support
modified eligibility, enrollment, data, and financial requirements; in
many states, the lead time on such major modifications is 18 to 24
months, putting the completion date for such changes after the January
2006 start date for the Part D benefit.
■ Communications between and among systems and agencies will
be key. Included are state Medicaid, aging, welfare, disability, social
services, pharmacy assistance and administrative agencies; county
governments; federal CMS, SSA, and HHS agencies; and finally, private
MA plans and PDPs that are not yet identified. This is a daunting task.
Data sharing will be critical to a strong and effective quality assurance
system, as well as for monitoring against potential fraud and abuse.
■ State 2006 budget requests are already due for consideration in the
2005 state legislative sessions. Medicaid and SPAP directors have little
information on which to base requests for specific activities.
■ The prescription drug component of states’ managed care rates will
have to be removed once Part D is implemented and recalculated for
future rate negotiations. In addition, states like New York that now
include drugs—both prescription and over-the-counter—in nursing
facility rates will need to modify and renegotiate them. This will be a
difficult and time-consuming process for states that are often governed
by strict state administrative procedure laws.
■ Some optional services, such as the provision of nonemergency
transportation to pick up and deliver prescription drugs, will no longer
be eligible for federal Medicaid matching funds. It seems unlikely that
Part D benefits will include coverage for this type of service, and Medic-
aid will not be able to continue payment because prescription drugs will
no longer be a Medicaid-covered service for many individuals.
■ Training of state staff is a major concern. This is particularly true
with regard to eligibility and enrollment. Most state eligibility workers
do not specialize; they handle workloads that include Temporary
Assistance for Needy Families, food stamps, Medicaid, and sometimes
a variety of other programs.
“If you’ve seen one
Medicaid program,
you’ve seen one Med-
icaid program.”
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■ Tension between CMS and states is currently very high in areas
of financial and programmatic interpretation. States noted that this
climate does not encourage the flexibility and good will that would
maximize the chance of effective cooperation in implementing the
Medicare drug benefit.
SUMMARY OBSERVATIONS
In addition to the specific issues and problems discussed on July 22, a
few key ideas seemed to generate a consensus among the state experts
during the day’s dialogue. While this is not an exhaustive list, the
items listed here represent ideas with compelling policy and adminis-
trative priority.
■ There is agreement that for many of the most frail and vulnerable
low-income individuals, an automatic enrollment process that enrolls a
maximum of eligible beneficiaries will be more likely to result in
continuity of coverage, as well as administrative simplification and
coordination. However, the auto-enrollment period may not be long
enough. States expressed the concern that some beneficiaries might
have difficulty gaining access to needed prescription drugs for the first
three to six months of 2006.
■ The Medicare drug benefit results in new and additional responsibility
for states at a time of financial crisis and revenue shortfalls across the
country. Although most states will eventually see savings from Medicare
Part D, those savings may be less than some observers believe. The
calculation techniques may limit savings, and administrative costs will
increase in almost all areas of Medicaid management. In addition, any
significant savings will not be realized for several years, long after states
will have invested funds in developing and executing new eligibility,
enrollment, and outreach processes and making systems changes.
■ Techniques to provide optimum integration of clinical care and drug
therapy will be critical to ensure high-quality and efficient service to
the dual eligible population. Some particular groups, such as the
severely mentally ill, will require close monitoring as the implementa-
tion process proceeds.
■ Specialized MA plans targeted toward low-income dual eligibles and
others with severe or disabling chronic conditions could go a long way
toward correcting the facets of the new program that will otherwise
make it much more difficult and expensive to integrate care and provide
disease management services to people with multiple chronic illnesses.
The statute includes several chronic care improvement demonstrations,
and states are hopeful that major commitments will be made to encour-
age the development of the demonstrations and new plans.
■ Education and marketing materials, as well as other publicly avail-
able explanations of the MMA changes, must consider the age, frailty,
and language and cultural challenges of elderly and disabled people. In
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addition, the very significant differences between the elderly and the
disabled must be reflected in all materials and outreach. Education and
information campaigns must be coordinated and consider the needs of
those residing in nursing homes, and those being served in home and
community-based programs.
■ It is important to keep in mind that Medicaid dual eligibles have a
comprehensive drug benefit now. Would a delay in their transition to
Medicare drug coverage be a worthwhile consideration, especially
since states will not be receiving significant short term savings from
Medicare because of the clawback? This could ensure that states and
Part D plans have all the necessary data-sharing arrangements in place
and that duals have been enrolled in a Part D plan with appropriate
transitions and continuity of care.
ENDNOTES
1. “Fact Sheet: Medicare and Prescription Drugs,” Kaiser Family Foundation, April 2003;
available at www.kff.org/medicare/1583-06-index.cfm.
2. An additional nine states have enacted laws to initiate SPAPs but have not yet imple-
mented them. For further information, see “The Basics: State Pharmacy Assistance
Programs” available at www.nhpf.org/pdfs_basics/Basics_SPAPs.pdf.
3. Automatic enrollment, in this case, will be designed to facilitate a seamless transition
from Medicaid to Medicare for dual eligibles, who are often frail and vulnerable individu-
als. If an individual does not choose a PDP within the allotted time period, he or she will be
automatically enrolled in a PDP that offers basic prescription drug coverage, is in the PDP
region where the individual resides, and has a monthly premium which does not exceed
the Part D premium subsidy amount.
4. “Medically needy” is an optional eligibility category under which the state permits
individuals to qualify for Medicaid by deducting the cost of the person’s medical care from
his or her monthly income when determining eligibility. This concept of “spending down”
to Medicaid eligibility is often used for elderly or disabled individuals who reside in nurs-
ing facilities, assisted living, or other community-based settings and who have high medi-
cal and/or prescription drug expenses.
5. For more information on the clawback calculation, see Andy Schneider, “The Clawback:
State Financing of Medicare Drug Coverage,” The Kaiser Commission on Medicaid and
the Uninsured, Washington, DC, June 2004; available at www.kff.org/medicaid/
loader.cfm?url=/commonspot/security/getfile.cfm&PageID=39919.
6. Congressional Budget Office, “A Detailed Description of CBO’s Cost Estimate for the
Medicare Prescription Drug Benefit,” Washington, DC, July 2004, 31; available at
www.cbo.gov/showdoc.cfm?index=5668&sequence=2#pt3.
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The term “dual eligible”* actually encompasses two groups of individuals who are served by both
Medicare and Medicaid:
Full benefit dual eligibles are low-income elderly and disabled individuals who are categorically and
financially eligible for the Medicaid program, as well as for Medicare. Therefore, they receive full
benefits under each program, including long-term care and prescription drugs. Six million individu-
als qualify as full benefit dual eligibles.
An additional 1 million Medicare beneficiaries are enrolled in voluntary Medicare Savings Programs
(MSPs), which were designed to assist low-income elderly and disabled individuals with paying for
Medicare cost sharing. This group of individuals does not receive full Medicaid benefits. MSP pro-
grams include:
■ Qualified Medicare Beneficiaries (QMBs) — Incomes below 100 percent of the federal poverty level
(FPL); Medicaid pays all Medicare cost sharing.
■ Specified Low-Income Medicare Beneficiaries (SLMBs) — Incomes between 100 and 120 percent FPL;
Medicaid pays Part B premium only.
■ Qualified Individuals (QIs) — Incomes between 120 and 135 percent FPL; Medicaid pays Part B
premiums only; subject to availability of state and/or federal funds.
*For more information on Medicare savings programs and dual eligibles and how they are defined, see “Dually Eligible for Medicare and Medicaid:
Two for One or Double Jeopardy?” NHPF Issue Brief 794, September 30, 2003, available at www.nhpf.org/pdfs_ib/IB794_Duals_9-30-03.pdf.
Co-Payc Above
Subsidy Group Assets Test Premium Deductible (generic/brand) catastrophic limit?d
Full Benefit Dualsa
<100% FPL N/A Noneb Noneb $1/$3
>100% FPL N/A Noneb Noneb $2/$5 No cost sharing
$6,000 individual
Below 135% FPL $9,000 couple Noneb Noneb $2/$5 No cost sharing
Up to limit, 15%
$10,000 individual co-insurance ; above
135% – 150%  FPL $20,000 couple Sliding scale $50 None limit,  $2/$5 co-pay
aIndividuals who are not living in an institution. Institutionalized duals are exempt from all cost sharing.
bNo premium is required if the individual selects a PDP whose premiums are less than or equal to an average cost plan.
cCopayment amounts will be indexed based on inflation and per capita growth in Part D expenditures.
dCatastropic limit is defined as the point at which an individual has spent $3,600 out of pocket on drugs.
APPENDIX A: Defining Dual Eligibles
APPENDIX B: Defining the Low-Income Subsidy
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10:00 am Registration — Coffee available
10:30 am Welcome, Introductions, and Overview of Issues
Judith D. Moore, Senior Fellow, National Health Policy Forum
Jennifer Ryan, Senior Research Associate, National Health Policy Forum
11:00 am ELIGIBILITY AND ENROLLMENT: OUTREACH FOR 2006
Kathy Kuhmerker, Deputy Commissioner, New York Office of Medicaid
Management
Kathleen Mason, Assistant Commissioner, New Jersey Department of Health
and Senior Services
John Wren, Aging Services Program Officer, DHHS Administration on Aging
11:45 am DUAL ELIGIBLES: MANAGING THE
TRANSITION AND CLINICAL CONCERNS
Mary Kennedy, Medicaid Director, Minnesota Department of Human Services
Tom Snedden, Director, Pennsylvania Pharmaceutical Assistance Contract
for the Elderly
James Verdier, Senior Fellow, Mathematica Policy Research, Inc.
Case Example: Mental Health – Carol Alter, MD,   Executive Director,
Treatment Effectiveness Now (TEN)
12:30 pm Lunch
1:00 pm STATE FINANCING ISSUES: ASSESSING SAVINGS AND COSTS
Chuck Milligan, Executive Director, UMBC Center for Health Program
Development and Management
Richard Figueroa, Legislative Director, California Department of Insurance
1:45 pm EVALUATING IMPACTS: RE-CAPPING
ADMINISTRATIVE AND SYSTEMS CHALLENGES
Barbara Edwards, Deputy Director, Office of Ohio Health Plans, Department
of Job and Family Services
All State Representatives
2:15 pm Wrap-up and Summary of Issues
2:30 pm Adjournment
(Appendix continued)
APPENDIX C: Agenda and Attendance List
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APPENDIX C, continued: Attendance List
Carol Alter
Executive Director
Treatment Effectiveness Now
Barbara Edwards
Deputy Director
Office of Ohio Health Plans
Ohio Department of Job and Family
Services
Richard Figueroa
Legislative Director
California Department of Insurance
Mary Kennedy
Medicaid Director
Minnesota Department of Human Services
Kathy Kuhmerker
Deputy Commissioner
Office of Medicaid Management
New York Department of Health
Kathleen Mason
Assistant Commissioner
Division of Senior Benefits and Utilization
Management
New Jersey Department of Health and
Senior Services
Chuck Milligan
Executive Director
Center for Health Program Development
and Management
University of Maryland Baltimore County
Matt Salo
Director
Health and Human Services Committee
National Governors Association
Tom Snedden
Director
Pharmaceutical Assistance Contract for the
Elderly
Pennsylvania Department of Aging
James Verdier
Senior Fellow
Mathematica Policy Research, Inc.
John Wren
Aging Services Program Officer
Center for Planning and Policy
Development
DHHS Administration on Aging
Participants
Kathryn Allen
Director
Medicaid & Private Health Insurance Issues
GAO
Cheryl Austein-Casnoff
Director, Division of State Children’s Health
Insurance
Family and Children’s Health Programs
Group
DHHS/CMS/CMSO
Cristina Boccuti
Analyst
Medicare Payment Advisory Commission
Jennifer Boulanger
Director
Health Policy
Johnson & Johnson
Jeffrey Buck
Associate Director
Center for Mental Health Services
DHHS/SAMHSA
Alice Burton
Director
State Health Group
AcademyHealth
William Clark
Director
Division of State Program Research
DHHS/CMS/ORDI/REG
State Experts
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Andrea Cohen
Health and Oversight Counsel (D)
Committee on Finance
U.S. Senate
Alissa Deboy
Special Assistant
Disabled and Elderly Health Programs
Group
DHHS/CMS/CMSO
Colette Desmarais
Health Policy Advisor (R)
Committee on Finance
U.S. Senate
Deirdre Duzor
Co-Director
Medicaid Pharmacy Team
DHHS/CMS/CMSO
Ryan Faden
Health Policy Associate
Policy and Government Affairs
American Public Human Services
Association
Kate Finnerty
Office Director
Washington D.C. Office
State of Delaware
Kim Fox
Senior Researcher
Center for State Health Policy
Rutgers University
Beth Fuchs
Principal
Health Policy Alternatives, Inc.
John Goetcheus
Assistant Counsel
Office of the Legislative Counsel
U.S. Senate
Jill Gotts
Health Insurance Specialist
Center for Beneficiary Choices
DHHS/CMS
April Grady
Analyst in Social Legislation
Domestic Social Policy Division
Congressional Research Service
Ginni Hain
Director
Division of Eligibility, Enrollment and
Outreach
Disabled and Elderly Health Programs
Group
DHHS/CMS/CMSO
Margo Harrison
Research Assistant
Medicare Payment Advisory Commission
Suzanne Hassett
Policy Coordinator
Office of the Secretary
DHHS/OS
Christine Hinds
Health Insurance Specialist
CMSO Pharmacy Team
DHHS/CMS
Jack Hoadley
Research Professor
Health Policy Institute
Georgetown University
Julianne Howell
Legislative Fellow
Office of Sen. John Kerry
U.S. Senate
Stephanie Hull
Executive Director
Center for Health Program Development
and Management
University of Maryland Baltimore County
Alexandra Huttinger
Policy Coordinator
DHHS/HRSA
Julie James
Principal
Health Policy Alternatives, Inc.
Participants (cont.)
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Curtis Kelley
Health Insurance Specialist
Office of Legislation
DHHS/CMS
Brendan Krause
Senior Health Policy Analyst
National Governors Association
Susan Lazaroff
State Advocacy Officer
American Psychological Association
Jean LeMasurier
Director, Health Plan Purchasing
Health Plan Benefits Group
DHHS/CMS/CBC
Michelle Lim
Research Associate
Health Insurance Reform Project
The George Washington University
Alice Litwinowicz
Senior Public Health Analyst
Office of Policy and Program Development
DHHS/HRSA
Ann McCormick
Social Science Analyst
Office of Human Services Policy
DHHS/OS/ASPE
Lisa McCormick Lavery
Associate Director
NJ Policy Forums on Health & Medical Care
Johanna Michaels
Legislative Correspondent
Office of Sen. John Kerry
U.S. Senate
Dave Michalik
Senior Administrator
Medicaid Program, Division of Social
Services
State of Delaware
Karen Nelson
Health Policy Director
Office of Rep. Henry Waxman
U.S. House of Representatives
Jennifer O’Sullivan
Specialist in Social Legislation
Domestic Social Policy Division
Congressional Research Service
Meghan O’Sullivan
Intern
Office of Disability, Aging and Long Term
Care Policy
DHHS/OS/OD
Lee Partridge
Health Policy Advisor
National Partnership for Women & Families
Josh Phillips
Congressional Liaison
Office of Legislation
DHHS/CMS
Kevin “Kip” Piper
Senior Advisor to the Administrator
Office of the Administrator
DHHS/CMS
Katiuscia Potier
Health Insurance Specialist
CMSO Pharmacy Team
DHHS/CMS
Susan Reinhard
Co-Director
Center for State Health Policy
Rutgers University
Hanaa Rifaey
Legislative Correspondent
Office of Sen. Maria Cantwell
U.S. Senate
Dottie Rosenbaum
Senior Policy Analyst
Office of Health Policy
Center on Budget and Policy Priorities
William Scanlon
Consultant
Rachel Schmidt
Senior Analyst
Medicare Payment Advisory Commission
Participants (cont.)
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Christine Scott
Specialist in Tax Economics
Domestic Social Policy Division
Congressional Research Service
Darlene Shughart
PACE Program
Pennsylvania Department of Aging
Cynthia Smith
Economist
Office of the Actuary
DHHS/CMS
David Smith
Attorney
Office of the General Counsel
DHHS/OS/CMS
Mimi Toomey
Manager of the Eldercare Locator
U.S. Adminstration on Aging
Karen Tritz
Analyst in Social Legislation
Domestic Social Policy Division
Congressional Research Service
Judith Wagner
Scholar in Residence
Institute of Medicine
Margaret Whitney
Intern
Office of Disability, Aging and Long Term
Care Policy
DHHS/OS/OD
Johanna Willer
Health Policy Intern
Division of State Program Research
DHHS/CMS/ORDI/REG
Claudia Williams
Consultant
AZA Consulting
Lisa Wilson
Special Assistant
Center for Medicaid and State Operations
DHHS/CMS
Carolyn Yocom
Assistant Director
Health Care Issues
GAO
Phyllis Zucker
Director
Policy Coordination
DHHS/AHRQ
Participants (cont.)
